JP2011505336A - 骨髄異形成症候群治療のためのシチジンアナログ - Google Patents

骨髄異形成症候群治療のためのシチジンアナログ Download PDF

Info

Publication number
JP2011505336A
JP2011505336A JP2010532071A JP2010532071A JP2011505336A JP 2011505336 A JP2011505336 A JP 2011505336A JP 2010532071 A JP2010532071 A JP 2010532071A JP 2010532071 A JP2010532071 A JP 2010532071A JP 2011505336 A JP2011505336 A JP 2011505336A
Authority
JP
Japan
Prior art keywords
patients
aza
azacitidine
azacytidine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010532071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505336A5 (cg-RX-API-DMAC10.html
Inventor
シー．エル．ベアクフ
トホマス バククストロム ジャイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2011505336A publication Critical patent/JP2011505336A/ja
Publication of JP2011505336A5 publication Critical patent/JP2011505336A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2010532071A 2007-11-01 2008-11-03 骨髄異形成症候群治療のためのシチジンアナログ Pending JP2011505336A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US98463807P 2007-11-01 2007-11-01
US99278107P 2007-12-06 2007-12-06
US3409308P 2008-03-05 2008-03-05
US8606908P 2008-08-04 2008-08-04
US9085208P 2008-08-21 2008-08-21
PCT/US2008/012430 WO2009058394A1 (en) 2007-11-01 2008-11-03 Cytidine analogs for treatment of myelodysplastic syndromes

Publications (2)

Publication Number Publication Date
JP2011505336A true JP2011505336A (ja) 2011-02-24
JP2011505336A5 JP2011505336A5 (cg-RX-API-DMAC10.html) 2011-12-22

Family

ID=40367738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532071A Pending JP2011505336A (ja) 2007-11-01 2008-11-03 骨髄異形成症候群治療のためのシチジンアナログ

Country Status (5)

Country Link
US (1) US20100311683A1 (cg-RX-API-DMAC10.html)
EP (1) EP2211870A1 (cg-RX-API-DMAC10.html)
JP (1) JP2011505336A (cg-RX-API-DMAC10.html)
CA (1) CA2742252A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009058394A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504857A (ja) * 2019-12-06 2023-02-07 ナネクサ・アクチボラグ 医薬組成物の製造のための新規プロセス
JP2023548111A (ja) * 2020-10-27 2023-11-15 ブイオーアール バイオファーマ インコーポレーテッド 造血悪性腫瘍を治療するための組成物および方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
AU2004289539C1 (en) 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
EP2396007A1 (en) 2009-02-10 2011-12-21 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
WO2012135405A1 (en) 2011-03-31 2012-10-04 Pharmion Llc Systhesis of 5-azacytidine
WO2013022872A1 (en) * 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
JP6162709B2 (ja) 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
PL2773360T3 (pl) 2011-11-03 2018-09-28 Millennium Pharmaceuticals, Inc. Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego
US9493500B2 (en) * 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
EP2970359B1 (en) * 2013-03-15 2021-04-07 Epigenetics Pharma LLC Fluorinated pyrimidine analogs and methods of use thereof
EP3052102B1 (en) * 2013-10-04 2019-12-04 Aptose Biosciences Inc. Compositions for treating cancers
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
EP3419631A4 (en) * 2016-02-26 2019-12-04 Epigenetics Pharma, LLC METHOD OF TREATING WILD TYPE TP53 TUMORS USING 2 ', 2'-DIFLUORO-5-AZA-2'-DEOXYCYTIDINE OR PRODRUGS THEREOF
WO2017189647A1 (en) * 2016-04-26 2017-11-02 Memorial Sloan Kettering Cancer Center Methods and compositions for the treatment of myelodysplastic syndrome
JP2021501203A (ja) 2017-10-30 2021-01-14 アプトース バイオサイエンシズ インコーポレイテッド がん治療用のアリールイミダゾール

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159347A1 (en) * 2001-04-24 2005-07-21 Dimartino Jorge F. Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase
WO2006063111A2 (en) * 2004-12-10 2006-06-15 Supergen, Inc. Pharmaceutical formulations cytidine analogs and derivatives
JP2010502602A (ja) * 2006-08-30 2010-01-28 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641758A (en) * 1993-11-10 1997-06-24 Kluge; Michael Cytarabine derivatives, the preparation and use thereof
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
WO2000055134A1 (en) * 1999-03-18 2000-09-21 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
NZ522767A (en) * 2000-05-15 2004-07-30 Celgene Corp Thalidomide and a topoisomerase inhibitor for the treatment of cancer
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
MXPA04011851A (es) * 2002-05-30 2005-03-31 Celgene Corp Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos.
MXPA05003889A (es) * 2002-10-15 2005-06-22 Celgene Corp Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
AU2003286836A1 (en) * 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
JP2007532641A (ja) * 2004-04-14 2007-11-15 セルジーン・コーポレーション 脊髄形成異常症候群の治療及び管理のための免疫調節化合物の使用法、及びそれを含む組成物
EP2043633B1 (en) * 2006-07-18 2016-07-06 University of Rochester Thiadiazolidinone derivatives for treating cancer
WO2008028193A2 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
DK3782612T3 (da) * 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159347A1 (en) * 2001-04-24 2005-07-21 Dimartino Jorge F. Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase
WO2006063111A2 (en) * 2004-12-10 2006-06-15 Supergen, Inc. Pharmaceutical formulations cytidine analogs and derivatives
JP2010502602A (ja) * 2006-08-30 2010-01-28 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6013026663; ＣＵＲＲＥＮＴ　ＴＯＰＩＣＳ　ＩＮ　ＭＩＣＲＯＢＩＯＬＯＧＹ　ＡＮＤ　ＩＭＭＵＮＯＬＯＧＹ，２０００，Ｖｏｌ．２４９，ｐ．１３５-１６４ *
JPN6013026665; ＪＯＵＲＮＡＬ　ＯＦ　ＣＬＩＮＩＣＡＬ　ＯＮＣＯＬＯＧＹ，２００２，Ｖｏｌ．２０，Ｎｏ．１０，ｐ．２４２９-２４４０ *
JPN6013026666; ＪＯＵＲＮＡＬ　ＯＦ　ＣＬＩＮＩＣＡＬ　ＯＮＣＯＬＯＧＹ，２０００，Ｖｏｌ．１８，Ｎｏ．５，ｐ．９５６-９６２ *
JPN6013026667; 最新医学，２００６，Ｖｏｌ．６１，Ｎｏ．３，ｐ．６０-６６ *
JPN6013026670; Ｍｅｂｉｏ，２００４，Ｖｏｌ．２１，Ｎｏ．３，ｐ．１１６-１２１ *
JPN6013026671; 血液・腫瘍科，２００７．０４．２８，Ｖｏｌ．５４，Ｎｏ．４，ｐ．４７５-４８１ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504857A (ja) * 2019-12-06 2023-02-07 ナネクサ・アクチボラグ 医薬組成物の製造のための新規プロセス
JP7828278B2 (ja) 2019-12-06 2026-03-11 ナネクサ・アクチボラグ 医薬組成物の製造のための新規プロセス
JP2023548111A (ja) * 2020-10-27 2023-11-15 ブイオーアール バイオファーマ インコーポレーテッド 造血悪性腫瘍を治療するための組成物および方法
JP7885211B2 (ja) 2020-10-27 2026-07-06 ブイオーアール バイオファーマ インコーポレーテッド 造血悪性腫瘍を治療するための組成物および方法

Also Published As

Publication number Publication date
CA2742252A1 (en) 2009-05-07
WO2009058394A1 (en) 2009-05-07
US20100311683A1 (en) 2010-12-09
EP2211870A1 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
US20100311683A1 (en) Cytidine analogs for treatment of myelodysplastic syndromes
Garcia-Manero et al. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
Baer et al. Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia
Issa et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
Cooper et al. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients
CN114727996A (zh) 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
Dombret et al. Acute myeloid leukemia in the elderly
Kebriaei et al. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation
Garcia-Manero et al. Hypomethylating agents and other novel strategies in myelodysplastic syndromes
WO2013022872A1 (en) Gene methylation biomarkers and methods of use thereof
Burnett et al. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia
Navada et al. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
US20210393665A1 (en) Low-intensity treatment of hematological disorders
TW201919705A (zh) 治療骨髓增生不良症候群之方法
US20250319111A1 (en) Methods of treating flt3-mutated hematologic cancers
JP2025020318A (ja) 骨髄異形成症候群を治療する方法
El-Jawahri et al. Phase II trial of reduced-intensity busulfan/clofarabine conditioning with allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoid leukemia
Zhao et al. Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome
Koseci et al. Prognostic Importance of Inflammatory Indexes in Patients Treated by Pazopanib for Soft Tissue Sarcoma.
Choi et al. Open-label, multicenter phase II study of combination therapy of imatinib mesylate and mycophenolate mofetil in pediatric patients with steroid-refractory sclerotic/fibrotic type chronic graft-versus-host disease
US20220152074A1 (en) Treatment of hematological disorders
Wang et al. Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients
Hamadani et al. Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia
Hilberink et al. Treatment of AML in Older
Loaiza-Bonilla et al. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130920

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140304